Change over period: —
NSE · ALIVUS
ALIVUS
-5.0% from the 52-week high · +68.0% above the low
Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra and currently employs 1,824 full-time employees. The company went IPO on 2021-08-06. The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.
The short version. Promoter holding was 74.85% in Sep 2026, down 0.15 points over 8 quarters.
1 · The price
How has the stock traded?
ALIVUS trades 5.0% below its 52-week high and 68.0% above its 52-week low.
4 · The owners
Who holds it, and are they adding?
Down 0.15 pts over 8 quarters.
Down 0.81 pts over 8 quarters.
Up 2.17 pts over 8 quarters.
+2 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 75.0 | 74.99 | 74.94 | 74.91 | 74.91 | 74.87 | 74.87 | 74.85 | -0.15 |
| FII | 6.74 | 6.57 | 6.42 | 6.84 | 5.09 | 5.29 | 5.54 | 5.93 | -0.81 |
| DII | 4.86 | 5.19 | 5.61 | 5.47 | 7.12 | 7.28 | 7.18 | 7.03 | +2.17 |
| Public | 13.4 | 13.25 | 13.03 | 12.78 | 12.88 | 12.56 | 12.41 | 12.19 | -1.21 |
Mutual fund holdings · Oct 2026
15 schemes hold this stock
13 the month before.
- Old Bridge Focused Fund4.13% of NAV
- the Quantum Small Cap Fund2.84% of NAV
- quant Healthcare Fund2.34% of NAV
- quant Flexi Cap Fund2.15% of NAV
- Unifi Flexi Cap Fund1.12% of NAV
- Bandhan Contra Fund1.0% of NAV
- Helios Small Cap Fund0.94% of NAV
- quant Small Cap Fund0.93% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for ALIVUS are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about ALIVUS
What is the ALIVUS share price?
ALIVUS (ALIVUS) last closed at ₹1,449.90, up 0.36% on the day. Its 52-week range is ₹860.05 to ₹1,520.70.
What is the market cap of ALIVUS?
ALIVUS has a market capitalisation of about ₹17,740 crore. Its price-to-earnings ratio is 26.6.
How are ALIVUS's latest results?
Promoter holding was 74.85% in Sep 2026, down 0.15 points over 8 quarters.
Who owns ALIVUS?
As of Sep 2026, shareholding was: Promoter 74.85%, FII 5.93%, DII 7.03%, Public 12.19%.
How many mutual funds hold ALIVUS?
15 mutual fund schemes held ALIVUS in October 2026. That compares with 13 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 01 Sep 2025 · Final Dividend - Rs. 5
- 17 Oct 2023 · Interim Dividend - Rs. 22.5
- 24 Mar 2023 · Interim Dividend - Rs. 21
- 15 Sep 2022 · Final Dividend - Rs. 10.5
- 22 Nov 2021 · Interim Dividend - Rs. 10.5
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.